Premium
Striational antibodies in a paraneoplastic context
Author(s) -
McKeon Andrew,
Len Vanda A.,
LaChance Daniel H.,
Klein Christopher J.,
Pittock Sean J.
Publication year - 2013
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.23774
Subject(s) - myasthenia gravis , medicine , thymoma , antibody , context (archaeology) , rheumatoid arthritis , cancer , titer , clinical significance , antibody titer , immunology , gastroenterology , biology , paleontology
ABSTRACT Introduction The clinical significance of striational antibodies (StrAbs) detected in the course of paraneoplastic antibody testing is unknown. Methods We compared all 203 striational antibody (StrAb)‐seropositive patients identified (2004–2005) during evaluation for paraneoplastic antibodies with age‐ and sex‐matched seronegative controls. Results Thymoma and myasthenia gravis (MG) were significantly more common among cases ( P <0.0001). Cancers more rarely detected after StrAb detection were adenocarcinoma in 5 patients and sarcoma in 3 patients. All patients who had a cancer identified after StrAb testing had a titer of ≥1:7680 or a coexisting muscle AChR‐binding antibody. Autoimmune disorders more commonly observed among cases (with any StrAb value) included: hypothyroidism; rheumatoid arthritis; and pernicious anemia (all P <0.05). Conclusions StrAbs may serve as a diagnostic clue for an autoimmune diagnosis. There is a low likelihood of oncological significance in patients with StrAb titers <1:7680 without coexisting paraneoplastic Abs. Muscle Nerve , 2013